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Abstract: 
 
Background: GE2, a human bifunctional Fcγ-Fcɛ fusion protein cross-links FcγRIIb and FcɛRI 
on human mast cells and basophils and results in inhibition of FcɛRI-mediated functions. 
Objective: Three modified Fcγ-Fcɛ (GE) proteins were compared with GE2 for their effect on 
inhibition of FcɛRI-mediated cellular responses. 
Methods: GE2 was modified to potentially improve its therapeutic efficacy by increasing 
binding to FcγRIIb (GE S mutant) and decreasing binding to FcγRIII (GE H mutant) or reversing 
the Fcγ and Fcɛ domains and removing nonhuman linker sequences (E2G). These proteins were 
tested for their ability to bind a basophil-like cell line, block FcɛRI-mediated degranulation in 
human basophils, and inhibit passive cutaneous anaphylaxis in human FcɛRIα-transgenic mice. 
Results: All 4 GE proteins bound cells that express FcɛRI and FcγRIIb, although the original 
GE2 retained the strongest ability to bind to these cells. E2G was as effective as GE2 in its 
ability to inhibit anti-Fel d 1 IgE-mediated histamine release from human basophils and block 
passive cutaneous anaphylaxis reactions. The GE S and GE H mutants were less effective. 
Conclusion: Optimization of GE2 as an inhibitor of FcɛRI-mediated functions showed that 
effectiveness was maintained when potentially immunogenic linker sequences were removed 
and Ig domain positions were reversed, but specific residue changes within the IgG CH2 domain 
aimed at enhancing GE2's inhibitory function by increasing FcγRII binding or additionally 
decreasing FcγRIII binding were not beneficial. 
Clinical implications: GE2 and E2G molecules are effective inhibitors of FcɛRI-mediated 
degranulation and are of interest as potential therapeutics for IgE-mediated allergic reactions. 
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Article: 
 
Abbreviations used 
 
HA: Hemagglutinin A 
ITIM: Immunoreceptor tyrosine inhibitory motif 
NP: 4-hydroxy-3-nitrophenylacetyl 
PCA: Passive cutaneous anaphylaxis 
 
Immediate hypersensitivity or allergic diseases, such as allergic asthma, allergic rhinitis, and 
most food allergies, are generally thought of as predominantly allergic antibody or IgE-mediated 
processes. The important role of IgE was recently highlighted by the inhibition of the early- and 
late-phase reactions in the lung and skin by treatment with anti-IgE.1, 2 The presence of allergic 
antibody to common environmental allergen is common and becoming more prevalent,3 and thus 
it is not surprising that diseases caused by IgE are also common and show increasing prevalence. 
IgE predominantly resides on mast cells and basophils bound to high-affinity IgE receptors, 
FcɛRI. In initiating an allergic response, FcɛRI-bound IgE binds multivalent allergens causing 
FcɛRI cross-linking. This triggers a signaling cascade that results in both immediate mediator 
release and production of other biologically active molecules causing the classic symptoms of 
allergy. 
 
We have previously shown that a human Ig fusion protein consisting of the hinge through CH3 of 
the γ1 heavy chain plus CH2 through CH4 of the ɛ heavy chain (GE2 protein) can block 
the allergic response by co–cross-linking FcɛRI and FcγRIIb inhibitory receptors on the cell 
surface.4, 5 GE2 is a fusion of the Fcγ1 hinge–CH2–CH3 and the Fcɛ CH2-CH3-CH4 that assembles 
as a 150-kd monomer containing 2 covalently linked Fcγ-Fcɛ chains. FcγRIIb is a negative 
regulatory molecule that contains an immunoreceptor tyrosine inhibitory motif (ITIM) and can 
inhibit FcɛRI signaling on mast cells and basophils.6, 7 GE2 blocks FcɛRI-mediated functions of 
human basophils and mast cells and inhibits passive cutaneous anaphylaxis (PCA) in FcɛRIα-
transgenic mice and skin test reactivity in rhesus monkeys with dust mite allergy.4, 8 GE2 also 
has the ability to inhibit Langerhans-like cell function through FcɛRI-FcγRIIb cross-linking9 and 
interfere in isotype switch and IgE production by B-cell function through FcɛRII (CD23)–FcγRII 
cross-linking.10 
 
In this article we compare the functional features of 4 proteins, the original GE2 and 3 GE2 
modified proteins that will be collectively referred to as GE proteins, constructed in an effort to 
enhance the ability of GE2 to inhibit IgE-mediated processes (Fig 1). One of the modified 
proteins, the GE S mutant, wherein the serine at position 267 is replaced by an alanine, was 
constructed to enhance binding to FcγRIIb.11 The second molecule, the GE H mutant, wherein 
the histadine at position 268 is replaced by an alanine, enhances binding to FcγRIIb, and 
decreases binding to FcγRIII.11A third protein, E2G, reversed the position of the Fcγ and Fcɛ 
domains, using the hinge region of Fcγ to function as the flexible linker between the 2 Fc regions 
and thereby removing potentially immunogenic linker sequences from the original construct. 
 
We found that E2G was as effective as GE2, whereas the GE S and H mutants were surprisingly 
less effective than the original GE2 molecule. They form monomers with a small percentage 
of dimers in the preparations, and all except for the GE S mutant were able to bind a 
human basophil cell line, Ku812, better than native IgE. The GE2 and E2G proteins inhibited 
cellular degranulation better than the GE S and GE H mutants in basophils isolated from one 
individual. Both GE2 and E2G were more effective in blocking IgE-mediated PCA responses in 
human FcɛRIα-transgenic mice than the GE S and GE H mutants. Overall, the effectiveness of 
these proteins to inhibit FcɛRI-mediated degranulation and PCA followed a pattern as follows: 
E2G = GE2 > GE S mutant > GE H mutant. 
 
 
Fig 1. Schematic diagram of human GE proteins. The molecules are depicted with the N-terminus on the left and 
the C-terminus on the right. The Fcγ domains (γ hinge-Cγ2-Cγ3) are striped, the Fcε domains (Cε2-Cε3-Cε4) 
are dotted, the flexible linker is black, and the hemagglutinin tag is white. Amino acid substitutions are designated 
by their IgG1 EU index position. 
 
Methods 
 
Gene construction and expression 
 
The GE2 construct, described previously,4 consists of a hemagglutinin A (HA) epitope, 7 vector 
amino acids, the IgG1 hinge-CH2-CH3, 17 amino acids including a (Gly4Ser)3 linker, 
and IgE CH2-CH3-CH4. We used nested PCR with primers 5′-GGCCAGATCTGA 
GCCCAAATCTTGT-3′, 5′-CCTCCCGCGGCTTTGTCTTGGC-3′, 5′-
TTGACCTCAGGGTCTTCGTGTGCCACGTCCACCACCACGCAT-3′, and 5′-
ATGCGTGGTGGTGGACGTGGCACACGAAGACCCTGAGGTCAA-3′ to introduce a S267A 
mutation within the IgG1 CH2 domain of our Fcγ-Fcɛ gene and named it the GE S mutant. A 
similar nested PCR strategy with primers 5′-TTGACCTCAGGGTCTTCCG 
CGCTCACGTCCACCACCACGCAT-3′ and 5′-
ATGCGTGGTGGTGGACGTGAGCGCGGAAGACCCTGAGGTCAA-3′ created the GE H 
mutant, containing H268A substitution. The BglII–SacII fragment was ligated into the 
GE2 expression vector.4 E2G reversed the Fcγ and Fcɛ sequences of GE2 by linking the 3′ end of 
IgE CH2-CH3-CH4 with the 5′ end of the IgG1 hinge-CH2-CH3 by using a BglII site. The HA tag, 
vector sequences, and (Gly4Ser)3 linker present in GE2 were removed. The 5′ κ leader 
sequence was connected to the IgE CH2 sequence by using overlap PCR and the primers 5′-
AAGCTTGATATCCACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTG
GGTTCCAGGTTCCACTGGTGAC-3′ and 5′-
TCCAGGTTCCACTGGTGACTTCACCCCGCCCACCGTGAAGATTTTACAGTCGTCCTG
CGACGGC-3′. The primer 5′-GGTACCAGATCTTTTACCGGGATTTACAGACACC-3′ was 
used to introduce a BglII site in place of the IgE stop codon. All the designed mutations were 
confirmed by sequencing. The product was cut with EcoRV-BglII and inserted into 
a plasmid containing a BglII site at the beginning of the IgG1 hinge and then placed in a final 
expression vector containing a CMV promoter (kindly provided by Dr S. L. Morrison). 
 
Protein expression and purification 
 
The linearized plasmid DNA (5 μg) was transfected by means of electroporation into 2 to 4 × 
107 Ns0/1 myeloma cells. Expression was tested by means of ELISA and metabolic labeling, and 
then GE protein–producing cells were subcloned and grown in roller bottles. The 
cell supernatant was passed through a protein A-sepharose column (Sigma Aldrich, St Louis, 
Mo), and bound protein was eluted with citric acid, pH 4.5. One-milliliter protein fractions were 
immediately neutralized with 2 mol/L Tris, pH 8.0, and then dialyzed with PBS. For analytic 
purposes only, a small fraction of each GE protein was separated by means of gel filtrationon 
a fast protein liquid chromatography by using two 25-mL Superose 6 columns (Pharmacia, 
Uppsala, Sweden) with PBS and 0.02% NaN3, pH 6.8, and a flow rate of 0.25 mL/min. The 
amount of monomer and aggregated material determined by means of an OD280 reading was 
quantitated by using Quanity One software (Bio Rad Laboratories, Inc., Hercules, Calif) and 
calculated as a percentage of the total protein eluted. The purified proteins were analyzed with 
SDS-PAGE under reducing and nonreducing conditions. 
 
Flow cytometry 
 
Binding to FcɛRI was assessed by means of flow cytometry on the human basophil-like cell line 
Ku812 (kindly provided by Dr W. Vainchenker, Creteil, France), which expresses FcɛRI and 
FcγRII. For each sample, 106cells were incubated with or without GE2 and IgE proteins at 
several concentrations at 4°C for 1 hour, followed by staining with fluorescein isothiocyanate–
labeled goat anti-human ɛ chain (Sigma Aldrich) for 30 minutes at 4°C. Samples were analyzed 
on a FACScan flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, Calif), 
gating out dead cells and debris. 
 
Histamine release 
 
Human basophils were isolated from the buffy coat of human blood, as described 
previously.4 The basophils were sensitized overnight with 10 μg/mL anti–4-hydroxy-3-
nitrophenylacetyl (NP) IgE. The next day, 0.01 to 20 μg/mL of each of the mutants, 10 μg/mL 
IgE, or 10 μg/mL IgG was added to the basophils for 2 hours in the incubator at 37°C. Cells were 
washed and activated with optimal concentrations of NP-BSA for 30 minutes. Histamine 
release was measured as described previously.7 
 
PCA 
 
Mice expressing human FcɛRIα but not murine FcɛRIα12 (kindly provided by J.-P. Kinet) were 
used to measure PCA, as described previously.4 Several concentrations of GE proteins in 50 μL 
of human serum from a subject with cat allergy diluted 1:5 or 0.5 μg/mL purified anti-Fel d 1 
human IgE were injected intradermally. Four hours later, the mouse was challenged 
intravenously with 200 μL of 1% Evan's blue dye in saline containing 10 to 15 μg of purified 
natural Fel d 1 (Indoor Biotechnology, Inc, Charlottesville, Va). After 30 minutes, the mouse 
was killed, and PCA was visualized by means of leakage of blue dye into the ventral surface of 
the skin through dilated blood vessels at the site of injection. PCA quantitation and end 
point titration was limited by the leaked dye appearance and distribution in the PCA spots, the 
locations of the skin injected, individual mice, and the number of sites per animal. Experiments 
were performed in triplicate. 
 
Results 
 
Characteristics of the purified GE proteins 
 
The GE2, GE S mutant, and GE H mutant proteins, when separated by means of SDS-PAGE 
under nonreducing conditions, appeared as approximately 150-kd monomers composed of paired 
covalently bound GE heavy chains in contrast to normal H2L2 IgE at 190 kd and BSA at 66 kd 
(Fig 2, A). E2G was slightly smaller than the other GE proteins, with a molecular weight of about 
145 kd, which is consistent with the removal of HA tag and linker sequences. A small fraction of 
the GE2- and E2G-purified material migrated at the approximate size of a GE protein dimer, or 
300 kd (see below). Under reducing conditions with β-mercaptoethanoland separation on SDS-
PAGE, the GE proteins migrated as a single band near 75 kd, as expected, whereas BSA 
appeared as a 66-kd band (Fig 2, B). When nondenatured protein samples were examined by 
using size exclusion chromatography, all 4 GE proteins contained a major peak, with the size of 
the expected GE protein monomers and a smaller fraction (2.8% E2G, 6.7% GE H mutant, 
17.3% GE S mutant, and 17.6% GE2) that migrated at about the expected size for dimers (data 
not shown). 
 
 
Fig 2. Purified GE proteins visualized on SDS-PAGE. A, Two micrograms of nonreduced samples of IgE isoforms, 
GE proteins, and BSA were run on a 5% phosphate gel. B, One microgram reduced samples of GE proteins and 
BSA were run on a 12% Tris-glycine gel. Molecular weight (MW) is indicated in kilodaltons on the right. 
 
GE proteins showed differential ability to bind to FcɛRI and FcγRIIb on Ku812 cells 
 
Given the sequence differences and changes in domain positions of the GE2 proteins, we 
examined the ability of these proteins to bind to receptors on a human basophil-like cell line, 
Ku812. Ku812 expresses FcɛRI and FcγRIIb, but not FcγRIIa and FcγRIII, on its surface.5, 13, 14 
The fusion proteins were predicted to bind cells better than IgE because they should bind to both 
FcɛRI and FcγRIIb, whereas IgE would only bind to FcɛRI. Using flow cytometry and a 
fluorescein isothiocyanate–conjugated goat anti-ɛ-chain antibody to detect GE proteins that 
bound Ku812 cells, we found that at low concentrations of protein, GE2, E2G, and GE H mutant 
proteins bound these cells at significantly higher levels than recombinant IgE (Fig 3). In 
comparison, GE2 displayed the highest level of binding to Ku812 cells, and the GE S mutant 
bound the least cells compared with the other GE proteins and IgE (Fig 3). 
 
 
Fig 3. GE proteins and IgE bind a basophil-like cell line, Ku812. Cells were incubated with several concentrations 
of IgE or GE proteins, and protein bindingwas measured as the percentage of α-ε fluorescein isothiocyanate–positive 
cells detected by means of flow cytometry. Error bars represent the SD among 3 repetitions. The GE H mutant at 5 
μmol/L had 1 measurement. 
 
GE proteins inhibit FcɛRI-mediated degranulation in human basophils 
 
We have previously shown that GE2 blocks FcɛRI-mediated histamine release in 
human basophils in a time- and dose-dependent manner.4 We compared the ability of the GE 
mutant proteins to inhibit degranulation of human basophils isolated from different donors with 
an undetermined number of receptors. Cell samples, prepared in duplicate or triplicate, were 
sensitized with 10 μg/mL NP-IgE and activated with optimal concentrations of NP-BSA. All 4 
GE proteins displayed an ability to decrease basophil degranulation; however, the extent of 
inhibition appeared to vary depending on the donor. In some donors GE2 and E2G were 
significantly more effective than the GE S and GE H mutants at 10μg/mL (Fig 4), whereas in 
other donors all 4 proteins displayed only minimal inhibition at 10 μg/mL, with no significant 
differences compared with the nonspecific IgE and IgG controls (Table I). The proteins also 
displayed a dose dependence that also varied depending on the donor cells used (Table II). In 
addition, when the GE proteins were tested on cells from the same donor over a 2-year time span 
at random intervals, the degree of inhibition varied, giving values of 10.3%, 25%, and 3.4% 
inhibition for GE2; 17.2%, 42.9%, and 37.6% for E2G; 5.7%, 17.5%, and 41.1% for the GE S 
mutant; and 24.1%, 40.9% and 33.6% for the GE H mutant (Table I, Table II, marked by 
asterisks). In all cases the IgE and IgG controls did not block degranulation, indicating histamine 
release was not inhibited by competition of FcɛRI binding between NP-IgE and IgE nor was 
FcγRIIb inhibitory signaling triggered solely by monomeric IgG. 
 
Fig 4. Effect of GE proteins on human basophil FcεRI-mediated degranulation. A, Basophils from a representative 
donor presensitized with 10 μg/mL anti-NP IgE, treated with 10 μg/mL protein, and activated with NP-BSA. 
Percentage of degranulation is taken from duplicate samples. 
 
Table I. Effectiveness of GE proteins on degranulation from basophils isolated from different 
donors 
Experiment Spontaneous ns IgE GE2 E2G GE S GE H ns IgG 
1∗ 6.5 (2.1) 43.5 (21.9) 39.0 (21.2) 36.0 (21.2) 20.0 (7.1) 32.5 (16.3) 42.5 (20.5) 
2 7.5 (0.7) 57.5 (3.5) 23.0 (1.4)† 24.5 (2.1)† 44.5 (10.6) 52.0 (7.1) 61.0 (5.7) 
3 9.5 (2.1) 47.5 (7.8) 24.5 (4.9)† 28.0 (2.8)† NA NA 43.5 (2.1) 
4 12.2 (9.9) 16.0 (11.4) 7.5 (0.1)† 8.7 (2.0) 16.9 (9.5) 12.3 (2.0) 47.3 (52.0) 
5 4.2 (1.6) 43.3 (5.9) 29.0 (9.6)† 23.7 (4.2)† 41.0 (10.0) 39.7 (5.1) 37.7 (15.3) 
6 9.0 (3.0) 29.3 (7.6) 18.0 (6.6) 19.7 (3.2) 23.0 (7.2) 19.7 (5.1) 30.7 (10.5) 
7∗ 4.0 (1.0) 49.7 (6.1) 48.0 (3.0) 31.0 (10.0)† 41.0 (8.7) 33.0 (8.5)† 51.3 (9.6) 
8 7.7 (5.7) 15.3 (4.9) 12.0 (3.6) 12.3 (1.5) 10.0 (4.6) 12.3 (4.5) 18.7 (2.1) 
9 10.0 (3.6) 42.0 (13.0) 47.3 (9.0) 35.0 (7.0) 40.7 (11.9) 44.3 (10.0) 45.0 (7.2) 
Percentage degranulation is reported in the presence of 10 μg/mL GE proteins, nonspecific IgE and nonspecific IgG, 
or spontaneous release showing SD (in parentheses). 
ns, Nonspecific; NA, not applicable. 
∗Identifying the same donor. 
†P < .05 compared with 10 μg/mL nonspecific IgE. 
 
Table II. Dose effect of GE proteins on degranulation tested on basophils isolated from several 
donors 
Protein Spontaneous ns IgE 0.01 μg/mL 0.1 μg/mL 1.0 μg/mL 10.0 μg/mL 20.0 μg/mL ns IgG 
GE2 2.5 (3.5) 39.0 (7.1) 41.5 (0.7) 42.5 (6.4) 33.0 (5.7) 35.0 (7.1) NA 43.0 (2.8) 
GE2∗ 7.5 (6.4) 28.0 (4.2) 33.5 (0.7) 30 (2.8) 26.0 (2.8) 21.0 (1.4) NA 32.5 (6.4) 
GE2 9.5 (2.1) 47.5 (7.8) NA 48.0 (4.2) 37.5 (7.8) 24.5 (4.9)† 18.5 (2.1)† 43.5 (2.1) 
E2G 2.5 (3.5) 39.0 (7.1) 41.0 (9.9) 38.0 (9.9) 40.0 (9.9) 37.5 (4.9) NA 43.0 (2.8) 
E2G∗ 7.5 (6.4) 28.0 (4.2) 27.0 (2.8) 23.0 (2.8) 21.0 (5.7) 16.0 (2.8)† NA 32.5 (6.4) 
E2G 9.5 (2.1) 47.5 (7.8) NA 44.5 (3.5) 39.0 (11.3) 28.0 (2.8)† 12.5 (3.5)† 43.5 (2.1) 
GE S 4.0 (1.0) 54.7 (10.2) 50.3 (2.1)† 48.7 (4.7)† 43.0 (10.1) 48.0 (3)† NA 53.0 (11.8) 
GE S 6.3 (1.5) 18.0 (5.3) 19.3 (7.2) 20.7 (6.8) 16.0 (6.2) 8.3 (6.5) NA 23.3 (9.5) 
GE S∗ 5.0 (3.6) 62.3 (15.2) 5.7 (16.1) 55.7 (10.5) 41.7 (16.9) 36.7 (12.7) NA 59.7 (14.6) 
GE S 10.7 (2.3) 41.3 (6.4) 28.7 (9.0) 24.7 (4.7)† 27.0 (5.3) 24.0 (7.2)† NA 37.3 (16.3) 
GE H 3.0 (2.8) 33.0 (5.7) 25.0 (4.2) 26.5 (3.5) 23.0 (2.8) 19.5 (2.1)† NA 33.0 (7.1) 
Percentage degranulation showing SD (in parentheses). 
ns, Nonspecific; NA, not applicable. 
∗Identical donor. 
†P < .05. 
 
GE2 and E2G blocked FcɛRI-mediated PCA in human FcɛRIα-transgenic mice more effectively 
than the GE S and GE H mutant proteins 
 
GE2 has been shown to inhibit FcɛRI-dependent PCA in mice when coadministered with anti-NP 
IgE and challenged with NP-BSA, as well as in mice presensitized with human serum from a 
subject with cat allergy and challenged with the native Fel d 1 antigen.4, 8 When we compared 
GE2 with the GE proteins, we found that E2G was equivalent to GE2 in blocking PCA at 5, 2.5, 
and 1 μg/mL (Fig 5, A). The GE S and GE H mutant proteins also completely blocked PCA 
reactivity at 5 μg/mL; however, both mutants displayed less inhibition of PCA reactivity than the 
original GE2 at lower concentrations (Fig 5, B and C). As a control, Fel d 1–specific IgE given 
without treatment of GE proteins resulted in a blue spot on challenge with Fel d 1, indicating 
strong positive PCA reactivity (Fig 5, panel 1). When nonspecific human myeloma IgE at 5 
μg/mL was mixed with Fel d 1–specific serum IgE, it did not block the PCA response (Fig 5, A, 
panel 5). Each comparison experiment was performed on at least 3 mice and produced consistent 
results, although the sensitivity to allergen and treatment varied slightly between animals. 
 
 
Fig 5. GE proteins block PCA: A, GE2 versus E2G; B, GE2 versus GE S mutant; C, GE2 versus GE H mutant; 
and D, size exclusion chromatography-purified E2G monomers versus E2G. Mice were injected with serum from a 
patient with cat allergy or purified IgE plus GE proteins and then challenged after 4 hours with Fel d 1 in Evans 
Blue dye. ∗Serum with 5 μg/mL myeloma IgE. 
 
Purified monomeric E2G more effectively blocked FcɛRI-mediated PCA than E2G preparations 
 
Because the GE protein preparations contained a small fraction of aggregated protein, we were 
interested in determining how this affected the inhibitory properties of the molecules. The 
effectiveness of our E2G preparations were compared with size exclusion chromatography–
purified E2G monomers (fractionated by Biogen Idec, Cambridge, Mass) by using PCA on 
FcɛRIα-transgenic mice sensitized with purified anti-Fel d 1 IgE. Both E2G preparations 
completely blocked at higher doses, whereas only monomer E2G blocked at the lowest dose of 
protein (Fig 5, D). 
 
Discussion 
 
The success of GE2 in blocking allergic responses in vitro and in animal models gives promise 
for this molecule as a potential novel treatment of human allergic diseases.4, 5 In seeking the best 
candidate for further drug development, we were interested in maximizing the benefits of co–
cross-linking FcγRIIb receptors with FcɛRI receptors on cells and minimizing the effects of 
potentially immunogenic sequences, such as a hemagglutinin tag and flexible linker. 
 
When we looked at GE protein binding to Ku812 cells, we found that GE2, E2G, and GE H 
mutant bound cells better than IgE, whereas the GE S mutant had poorer binding than IgE. The 
lower binding of the GE mutants compared with that of GE2 was unexpected because previous 
studies by Shields et al11 showed an increase in binding affinity (ratio of mutant/native intact Ig) 
of 1.84 for FcγRIIb (S267A), 1.44 for FcγRIIb, and 0.54 for FcγRIII (H268A). These small 
differences in binding of intact IgG molecules did not appear to correlate with an improved 
inhibitory effectiveness of the GE proteins. In the Ku812 cell model, the binding of the GE 
proteins measures the sum of the binding to both FcγRII and FcɛRI. It is possible that the higher 
percentages of GE2-, E2G-, and GE H mutant–bound cells compared with lower binding of the 
GE S mutant could suggest that even though the Fcγ mutation increased binding under the Ig 
configuration (H2L2), the mutation could play an inhibitory role by directly blocking Fcγ access 
to FcγRII under the Fcγ-Fcɛ configuration. Likewise, this mutation might impede binding of the 
Fcɛ portion to FcɛRI indirectly through the mutation, through an induced conformational 
change of the GE S mutant, or both. It was a concern that the lower binding of the GE S mutant, 
although only slightly less than that of IgE, might be partially due to the presence of aggregates 
in the preparation. Although an effort was made to isolate monomeric proteins, the aggregates 
could reform in solution after monomer purification. However, other factors must be involved in 
the lower binding seen for the GE S mutant because both GE2 and the GE S mutant contained 
similar concentrations of aggregated material (17.6% and 17.3%, respectively), and the overall 
binding was still greater for GE2 over the GE S mutant. This indicated that the difference in 
protein composition, a single amino acid residue in the FcγR binding region, likely changed the 
physical properties of the GE mutants, affecting binding affinity through a mechanism such as 
improper protein folding, decreased stability of the protein on the cell surface, or faster uptake 
and degradation in the Ku812 cell line. 
 
FcɛRI-mediated responses can be inhibited when FcɛRI is coaggregated with FcγRIIb by original 
GE2 on basophils and cord blood–derived human mast cells.6, 4, 7, 15 In some donors tested in this 
study, GE2 and E2G significantly inhibited degranulation compared with the GE S and GE H 
mutants that was consistent with the trend seen in the PCA studies. However, our basophil 
studies also showed that the GE proteins displayed differences in the level of inhibition between 
donors such that the proteins did not always show the same pattern of effectiveness. We also 
observed variability in GE protein effectiveness by using the same donor taken over time, 
suggesting that human basophils might have different phenotypic states that affect inhibition 
through the FcγRIIb receptor. Variation between and within subjects for in vitro basophil release 
is a well-recognized phenomenon. 
 
It is likely that the number of receptors on the surface of the cells plays an important role in this 
process. Studies suggest that FcγRIIb expression is altered by a polymorphic promoter for human 
FcγRIIb,16, 17 FcγRIIb expression on germinal center B cells in mice can be altered by 
older follicular dendritic cells,18 and other studies show donor variability of FcγRII isoform 
expression in human monocytes,19 platelets,20 and natural killer cells.21 Thus the expression of 
IgE and IgG receptors on human basophils and especially FcγRIIb and FcγRIIa expression on 
basophils from donors in whom no inhibition was observed are a likely factor in the different 
donor cell degranulation responses. 
 
In addition to measuring histamine release from human basophils in vitro, we have measured the 
effects of GE2 on PCA in FcɛRIα-transgenic mice. The mast cells in these transgenic mice bind 
the human Fcɛ of the GE proteins through their human FcɛRIα chain while the murine FcγRIIb 
will bind the human Fcγ portion. E2G appeared to be equally as effective as GE2 in its ability to 
block PCA reactivity, whereas the GE S mutant and GE H mutant required higher doses of GE 
protein to completely block PCA reactivity. These results suggest that the mutations intended to 
increase binding to the FcγRIIb receptor might negatively affect ITIM signaling. High 
concentrations of nonspecific IgE were unable to block PCA reactivity, indicating that the GE 
proteins block FcɛRI signaling specifically and not by competition with IgE for receptor. 
 
In our GE protein preparations the small percentage of high-molecular-weight material appeared 
to represent denaturation of protein during the acidic elution from the protein A-sepharose 
column that did not properly refold on neutralization. Purified E2G monomer, which was able to 
block PCA reactivity at lower doses of protein (Fig 5), was more potent than the original E2G 
preparation. Although size exclusion chromatography–purified protein showed greater PCA 
activity, the differences did not appear to have a large affect on the comparison of the GE 
proteins. The GE2 and GE S mutant preparations contained the highest fraction of aggregate, 
suggesting that they would have the largest shift in effectiveness; however, the binding and 
inhibitory activity of the GE S mutant was significantly less than that of GE2. The GE H mutant 
and E2G preparations contained much less aggregate, yet did not perform dramatically better 
than GE2. 
 
Overall, we have found that the GE2 and E2G constructs were the most effective inhibitors of 
IgE-mediated degranulation and showed the highest binding to a basophil-like cell line. 
Although the Fcγ and Fcɛ binding sites appeared to be functional in both 5′ and 3′ positions in 
the molecule, the E2G structure theoretically would have an advantage over GE2 in terms of the 
potential side effects derived from the potentially immunogenic linker sequences because the 
artificial synthetic linker sequence in GE2 was replaced by the natural IgG hinge region in E2G. 
Therefore E2G not only lacks the artificial linker sequence but also only has 1 fusion junction 
instead of 2 fusion junctions in GE2. For the GE S and GE H mutants, the lower Ku812 binding 
and decreased inhibition of histamine release compared with that of GE2 and E2G suggest that 
the serine residues at position 267 and the histidine residue at position 268 in the CH2 domain 
of IgG1 are important in ITIM signaling. Amino acid substitutions, which have been shown to 
increase binding to the FcγRII receptors, decreased the effectiveness of the inhibitory properties 
of the GE molecules. It is possible that slightly lower affinity binding is critical for co–cross-
linking of FcγRII and FcɛRI receptors and necessary for ITIM signaling. Cell-surface movement 
of the receptors might be restricted, or receptor recycling could be affected as well. 
 
In conclusion, given that GE2 and E2G are the most effective inhibitors of the 4 molecules, it 
would be beneficial for further drug development to consider both GE2 and E2G molecules as 
viable therapeutic options because the immunogenicity of the (Gly4Ser)3 flexible linker has not 
been determined. 
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